The short answer on ChondroFiller candidacy

Most patients assessed for ChondroFiller treatment are carrying Outerbridge (ICRS) Grade III or IV cartilage damage — partial- to full-thickness loss that causes meaningful pain and functional limitation but stops short of the end-stage joint destruction that typically requires replacement surgery.

Two eligibility tracks exist. The first is a focal contained defect: a discrete area of Grade III or IV cartilage loss with an otherwise mechanically sound joint. The second, and increasingly common, track is diffuse osteoarthritis at Kellgren-Lawrence Grade III or IV — where wear is spread across a broader area of the joint surface rather than concentrated in a single lesion. The ultrasound-guided injectable collagen scaffold pathway is suited to both, because the scaffold coats the joint surface as an additive layer and supports the body's own repair processes through acellular matrix-induced chondrogenesis, rather than requiring a precisely shaped defect bed.

There is no fixed upper age limit for the injectable pathway. Joint-preservation use in patients in their 60s and 70s is well recognised in published clinical experience.

Grade I changes and early Grade II changes — surface softening without significant depth of loss — do not meet the formal treatment threshold.

What Grade III and IV cartilage damage actually means

The Outerbridge scale — also referred to as the ICRS grading system — runs from Grade I (surface softening, no significant depth of loss) through to Grade IV (complete cartilage loss down to exposed bone). ChondroFiller targets the more significant end of that range.

Grade III means the cartilage has worn away to more than half its original thickness. The underlying bone is still covered, but the protective layer is substantially reduced — this is the point at which most patients begin experiencing consistent mechanical pain.

Grade IV describes full-thickness loss: the cartilage is gone in places and the bone beneath is directly exposed. It is the most severe category before multi-compartmental joint destruction sets in, and it remains within the treatment window for the injectable pathway provided the overall joint architecture is still viable.

Grading is typically determined by MRI scan, though arthroscopic assessment provides the most definitive picture. Patients who have had imaging may see these grades noted in their radiology report or consultant letter.

The parallel classification used for osteoarthritis — the Kellgren-Lawrence scale — grades joint changes differently, and the next section explains how that system maps to eligibility.

Osteoarthritis presentations and the injectable pathway

Osteoarthritis differs from a focal traumatic defect in an important way: rather than a discrete area of damage, wear at Kellgren-Lawrence Grade III or IV is typically distributed across the joint surface, often affecting multiple contact zones simultaneously. Focal surgical techniques depend on a contained defect bed with healthy surrounding cartilage — they are not well suited to this pattern. The injectable pathway is.

Kellgren-Lawrence Grade III and IV represent the most common starting point for injectable ChondroFiller assessment. Grade III involves significant joint space narrowing with osteophyte formation visible on imaging; Grade IV shows severe narrowing with subchondral sclerosis. Both grades indicate substantial cartilage loss whilst the broader joint architecture may still be viable enough to support a scaffold-driven repair response. End-stage, multi-compartmental destruction falls outside the treatment window — at that point the biological environment required for the scaffold to work is no longer reliably intact.

The same injectable approach is used beyond the knee. Hip OA and small-joint presentations — including the ankle — are treated through this pathway when surrounding structures remain mechanically sound.

Because OA is a more recent addition to the ChondroFiller indication set than focal cartilage defects, patient-selection criteria are still being refined in clinical practice. In practical terms, specialists may apply somewhat different thresholds depending on the individual clinical picture, which makes thorough MRI review and a specialist consultation essential before any decision is made.

Specific presentations that often qualify

Several injury histories recur consistently among patients who proceed to a positive candidacy assessment.

If you have a history of a sporting injury or accident that caused direct cartilage damage — a post-traumatic chondral lesion — this is one of the most well-established indications, provided the surrounding joint has remained or been made mechanically stable.

If you have been diagnosed with osteochondritis dissecans (OCD) — a condition in which a segment of cartilage and bone can loosen or partially detach from the joint surface — the injectable pathway is a recognised option when the defect meets the grade threshold.

If cartilage damage followed a meniscal tear or ligament reconstruction, the underlying cause has already been addressed in many cases. Candidacy depends on whether the joint mechanics are now sound; residual instability or malalignment would need correction first.

If you are in your 60s or 70s, the clinical question is not your age but your joint picture: MRI findings showing viable surrounding cartilage, adequate subchondral bone, and single-compartment rather than whole-joint destruction are the factors that determine whether the scaffold has an environment in which to work. Those variables are assessed at consultation — age alone is not a disqualifier.

A specialist review is needed to confirm suitability in any of these scenarios.

Prerequisites, exclusions, and who won't be suitable

Not all suitability barriers carry the same weight, and the distinction matters for patients worried they are automatically excluded.

Conditions that need to be corrected first

Joint mechanical stability is a shared prerequisite across all ChondroFiller pathways. The injectable collagen scaffold relies on a functional biological and mechanical environment to recruit the body's own repair cells — it cannot compensate for underlying structural problems. Untreated ligament laxity, leg malalignment greater than approximately 5°, and meniscal deficiency that is actively driving cartilage wear must each be addressed before or alongside treatment.

These are not permanent exclusions. Patients who undergo alignment correction, ligament reconstruction, or meniscal repair may become suitable candidates once the mechanical environment has been restored. The practical question at assessment is whether that corrective work has been done, not whether the problem ever existed.

Absolute contraindications

A separate group of factors rules out treatment regardless of the joint picture:

• Known hypersensitivity to rat-derived (murine) collagen — anyone with a history of sensitivity to animal-derived collagen proteins should raise this specifically at their specialist appointment
• Active joint infection (septic arthritis)
• Inflammatory joint conditions, including rheumatoid arthritis, gout, and pseudogout
• Active cancer or haematopoietic (blood-cell) disorders
• Pregnancy or breastfeeding

Beyond these absolute contraindications, there is a practical ceiling: when joint destruction has progressed so far that very little viable cartilage or joint space remains across multiple compartments, the scaffold has insufficient biological tissue to work within. At that stage, joint replacement is typically the more appropriate clinical discussion — but reaching that point is not the same as meeting one of the absolute contraindications listed above.

Most patients presenting with focal cartilage damage or moderate-to-severe OA will not meet these criteria. A specialist consultation with MRI review is the clearest way to establish which category applies.

Realistic outcomes and how to find a specialist

Published data give a reasonably consistent picture of what patients assessed for ChondroFiller injectable treatment can expect. Across knee, hip, and small-joint cohorts, IKDC scores improve by approximately 30 points at 12 months, and 70–85% of treated patients achieve significant symptom relief — meaningful reductions in pain alongside measurable improvements in mobility. The safety profile is notably favourable: reported complication rates are approximately 0%, with a reoperation rate of 3–8% in published series. By comparison, microfracture carries reoperation rates of up to 41%, and ACI/MACI procedures are associated with complication rates of up to 17%, though study designs differ and direct head-to-head comparisons should be treated with appropriate caution.

One limitation is worth naming plainly: much of the available evidence derives from manufacturer-sponsored clinical evaluation reports rather than independently funded randomised controlled trials, and follow-up data beyond 24 months remain limited. The data that do exist are internally consistent, and the safety record is well-documented — but longer-term evidence is still accumulating.

Ultimately, imaging establishes whether the joint picture falls within the eligibility range; clinical examination determines whether it actually does for an individual patient. A specialist assessment is the only reliable route to that answer.

Search MSK lists specialists across the UK who offer ChondroFiller injectable treatment — use the region and specialty filters to find a clinician suited to your situation.